Pre-market high-volume: 6L9.F ViewRay (XETRA) €0.03 03 Feb 2026, watch liquidity

Pre-market activity shows 6L9.F stock trading at €0.025 on XETRA in Germany on 03 Feb 2026, after a sharp intraday move from the prior close of €0.001. Volume surged to 3,500 shares versus an average of 279, giving a relative volume of 12.54. The combination of extreme volume and a 1‑month change of +2400.00% makes 6L9.F a clear high-volume mover in the healthcare medical‑devices segment this morning.

Price action and high-volume signal for 6L9.F stock

The immediate price fact is €0.025 versus a previous close of €0.001. The one‑day pre-market jump shows Change +0.024 (2400.00%) and a day high €0.025. Trading volume of 3,500 is well above the avgVolume 279, indicating short-term interest and liquidity reappearing. Market cap stands at €207,228,256.00 and shares outstanding are 8,289,130,240. For active traders, the short time window and thin order book on XETRA can produce rapid fills and slippage.

Fundamental snapshot and valuation metrics for 6L9.F stock

ViewRay, Inc. (6L9.F) lists in Healthcare, Medical – Devices. Trailing EPS is -0.55, giving a negative PE around -0.05. Price to sales is 2.39 and price to book is 0.06, reflecting a low market price versus book. Cash per share is 0.75 and current ratio is 2.36, showing short‑term liquidity. Debt to equity is 1.05, which raises leverage concerns for a small‑cap device maker. These metrics explain why the stock can move dramatically on small flows.

Technical context, averages and trading ranges for 6L9.F stock

Short-term averages show a 50‑day at €0.32 and 200‑day at €2.72, both far above the current trade. The 52‑week range runs €0.0005 to €4.60, so the stock remains deeply below long‑term averages. Fast mean reversion is possible but requires sustained demand. Traders should note wide gaps between price and moving averages, and the risk of pump‑and‑dump dynamics in low‑priced securities on XETRA.

Meyka AI rates 6L9.F with a score out of 100 and forecast

Meyka AI rates 6L9.F with a score of 57.47 out of 100 (Grade C+, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12‑month reference price of €0.10, which implies an upside of 300.00% from €0.025. Forecasts are model‑based projections and not guarantees. The grade and projection reflect mixed fundamentals, modest cash per share, and high volatility.

Risks, catalysts and sector context for 6L9.F stock

Key risks include continued negative earnings, leverage, and thin trading that magnifies moves. Catalysts would be firm order announcements for MRIdian systems or positive clinical adoption news. The Healthcare sector in Germany has a modest recent performance (1M +0.82%), but medical‑devices show differentiated demand. Regulatory or contract news remains the primary driver for sustained gains in ViewRay, Inc.

Trading implications and strategy for high-volume movers like 6L9.F stock

Given the large intraday move, short‑term traders should size positions for rapid stop‑outs and expect wide spreads on XETRA. Use limit orders and watch relative volume and order book depth. For longer‑term investors, contrast the current price with book value €0.46 per share and cash per share €0.75. Review company filings and announcements on the ViewRay website and our internal page at Meyka stock page before adjusting allocations.

Final Thoughts

6L9.F stock is a classic high‑volume mover pre-market on XETRA on 03 Feb 2026, trading at €0.025 on volume of 3,500 shares and showing a relative volume 12.54. Short-term momentum is real, but fundamentals remain mixed: negative EPS -0.55, debt/equity 1.05, and a price far below 50‑ and 200‑day averages. Meyka AI’s grade (C+, 57.47/100) flags a HOLD stance while the model projects €0.10 in 12 months, an implied 300.00% upside from today’s price. Forecasts are model‑based projections and not guarantees. For traders, the setup warrants tight risk controls and a watch on news flow. For investors, validate clinical adoption and order cadence before increasing exposure. Meyka AI, an AI‑powered market analysis platform, tracks updates and liquidity for active monitoring.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.